We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Excessive Repeat Lipid Testing Wastes Healthcare Resources

By LabMedica International staff writers
Posted on 01 Oct 2013
The experiences of clinical laboratory pathologists support the conclusion that as many as one-third of coronary heart disease (CHD) patients have unnecessary repeat lipid testing.

It is widely recognized within the laboratory medicine profession that many physicians regularly order inappropriate medical tests and that this has been a problem for decades and is the source of copious wasteful spending.

Scientists at the Veterans Affairs Medical Center (VAMC, Houston, TX, USA) identified 27,947 patients with CHD who were taking a variety of lipid-lowering medications and who had attained the guideline-recommended low-density lipoprotein (LDL) cholesterol target of less than 100 mg/dL. More...
The mean age of these study subjects was 73 years, and most of the patients were white males. The prevalence of hypertension was 86%, and that of diabetes was 44%.

The study subjects had well-controlled lipid levels, with excellent mean baseline levels of LDL cholesterol of 70 mg/dL, non-high density lipoprotein (HDL) cholesterol of 94 mg/dL, triglycerides of 123 mg/dL, and HDL cholesterol of 43 mg/dL, and 72% were taking statins. A total of 9,200 underwent repeat lipid panels within 11 months, without any intensification of their treatment. This ruled out any patients who might have been attempting to reach an even lower LDL cholesterol target of less than 70 mg/dL.

A total of 34% of the repeat lipid tests were done within six months of an index test, and 80% were done within nine months. Their results were strikingly similar to those of the index lipid panels, which also argues against major medication or therapeutic lifestyle changes as the drivers of repeat lipid testing. A sensitivity analysis involving a subset of 13,114 patients who had optimal of below 70 mg/dL LDL levels, showed that 62% underwent repeat lipid testing, confirming that redundancy was commonplace even in these patients.

The study showed that patients with concomitant high blood pressure or diabetes as the most likely to undergo repeat lipid panels, although redundant testing is commonplace even in healthy patients. Salim S. Virani, MD, PhD, the senior author of the study, said, “There is a tendency of health care providers to order frequent laboratory testing in complex patients. Frequent lipid testing in these patients likely represents providers’ practice to order comprehensive laboratory tests, including lipid levels, rather than focusing on one clinical issue, for example, ordering only glycated hemoglobin (HbA1c) measurement to assess diabetes control.” The study was published online on August 12, 2013, in the journal JAMA Internal Medicine.

Related Links:

Veterans Affairs Medical Center




New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.